A proposal that would financially incentivize doctors to administer biosimilars in Medicare Part B over their higher-cost reference biologics is among the amendments that the Senate Finance Committee may reconsider as it continues working on its pharmacy benefit manager reform package.
The committee advanced its PBM reform bill, the Modernizing and Ensuring PBM Accountability (MEPA) Act on 26 July. (Also see...







